WHAT: Western University and Sumagen Canada will hold a briefing for media and London’s research community regarding preliminary results for the first-ever human applied clinical study (SAV CT 01) of the world’s only preventative HIV vaccine based on a genetically modified killed whole virus (SAV001-H), which was initiated in March 2012.
Last year, SAV001-H received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.
WHEN: Tuesday, November 6, 2012 at 11 a.m.
WHERE: Siebens Drake Research Institute, Room 217, Western University, London, Ontario
WHO: Dr. Chil-Yong Kang of Western’s Schulich School of Medicine & Dentistry and Dr. Dong Joon Kim of Sumagen Co. Ltd.
Media is advised parking is available at Dental Parking Lot (C) and Social Science Lot (J).